Merck's first-quarter results beat expectations amid healthy vaccine-sales growth
Merck & Co Inc MRK
News
-
Merck Announces First-Quarter 2024 Financial Results
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
Merck Up Nearly 5%, on Track for Record High Close — Data Talk
Trending: Merck Wins FDA Green Light for Winrevair
Thinking about buying stock in Diamondback Energy, Merck, High Tide, Rumble, or SNDL?
Merck's stock rallies toward a record after FDA OKs arterial-hypertension drug
Stocks to Watch: GameStop, Merck, Bowman Consulting
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
Merck shares rise on FDA approval for Winrevair
Merck Shares Rise 5% on FDA Approval for Winrevair
Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region
Merck's Phase 3 Lung Cancer Study of Keytruda-Lynparza Combo Misses Main Endpoints
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform